The Economic Times Healthcare and Biotech News This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Aurobindo Pharma gets tax demand of over Rs 13 cr, including interest, penalty
Aurobindo Pharma Ltd confronts Rs 13 crore tax demand, ordered by Deputy Commissioner (ST) STU-1. The demand includes ITC reversal, GST payment with interest, and penalty. The company plans appeal with no financial impact reported. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - May 3, 2024 Category: Pharmaceuticals Source Type: news

Dr Reddy's launches generic anti-bacterial drug in US
The company's product is a therapeutic generic equivalent of Oracea capsules (40 mg) approved by the US Food and Drug Administration (USFDA). (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - May 3, 2024 Category: Pharmaceuticals Source Type: news

Bharat Biotech says its Covaxin demonstrated ‘excellent safety records’
Bharat Biotech has emphasized the safety of its Covaxin Covid vaccine, stating that it has shown excellent safety records with no vaccine-associated incidents such as blood clots or other serious side effects. The company highlighted that Covaxin was developed with a focus on safety first, followed by efficacy. It mentioned that Covaxin was extensively evaluated in more than 27,000 subjects during its licensure process and has been continuously monitored for safety by the health ministry. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - May 2, 2024 Category: Pharmaceuticals Source Type: news

Bayer acquires remaining 25% stake in Bayer Zydus Pharma Pvt Ltd to secure full ownership
Bayer Pharmaceuticals Private Limited and Zydus Lifesciences Limited have concluded their joint venture, Bayer Zydus Pharma Private Limited (BZPPL), established in 2011 for pharmaceutical sales and marketing in India. Bayer is now acquiring full ownership of the entity as per pre-agreed terms. The joint venture successfully combined Zydus's Indian marketing expertise and distribution network with Bayer's global innovation, making strides in various therapeutic areas. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - May 2, 2024 Category: Pharmaceuticals Source Type: news

Maiva Pharma raises Rs 1,000 cr from Morgan Stanley PE and India Life Sciences Fund
Maiva Pharma has raised Rs 1,000 crore from Morgan Stanley Private Equity Asia and India Life Sciences Fund, including both primary and secondary funding. The funds will be used to set up a new manufacturing facility near Karnataka's Hosur, with capabilities in sterile dosage forms, including pre-filled syringes, bags, oncology, and hormonal injectables. Maiva's complex injectables development and manufacturing capability, strong compliance and regulatory standards, and transparency differentiate the company from competitors. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - May 2, 2024 Category: Pharmaceuticals Source Type: news

Maiva Pharma raises Rs 1000 crore from Morgan Stanley Private Equity, InvAscent
Morgan Stanley PE Asia and India Life Sciences Fund are investing almost equally, total stake with both funds combined will be over 60% post primary investment, the company told ET. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - May 2, 2024 Category: Pharmaceuticals Source Type: news

Concerns raised over Covishield vaccine safety in India's apex court
A plea has been filed seeking setting up of an expert medical panel to study and assess the possible risk factors associated with the Astrazeneca's Covishield vaccine, which was one of two vaccines administered in India against Covid-19. Advocate Vishal Tiwari in his fresh application said that AstraZeneca had accepted a link between the vaccine and Thrombosis with Thrombocytopenia Syndrome (TTS). (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - May 1, 2024 Category: Pharmaceuticals Source Type: news

Covishield row: AstraZeneca reaffirms vaccine safety amidst rare 'side effect' concerns
(Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - May 1, 2024 Category: Pharmaceuticals Source Type: news

Covishield vaccine: Plea filed in SC seeking formation of expert panel to study side-effects, risk factors
A petition filed in the Supreme Court seeks the formation of a medical panel from AIIMS, Delhi to study Covishield's side effects. It demands supervision by a retired SC judge and urges the government to establish a compensation system for severe disabilities or deaths caused by the vaccine during the pandemic (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - May 1, 2024 Category: Pharmaceuticals Source Type: news

Covishield Vaccine Case: AstraZeneca expresses 'sympathy' for those who lost loved ones
Covishield Vaccine Row: Following AstraZeneca's acknowledgment of a rare side effect associated with its COVID-19 vaccine, known as Covishield in India, the UK pharmaceutical giant extended sympathy to those impacted. Reaffirming its dedication to patient safety amidst concerns about potential rare side effects, AstraZeneca emphasised the vaccine's overall safety profile. The company underscored the stringent standards of regulatory authorities to ensure the safe use of medicines, including vaccines. AstraZeneca highlighted the extensive clinical trial data and real-world evidence consistently supporting the safety and eff...
Source: The Economic Times Healthcare and Biotech News - May 1, 2024 Category: Pharmaceuticals Source Type: news

Covishield side effects: AstraZeneca expresses 'sympathy' for those who lost loved ones
Following AstraZeneca's acknowledgment of a rare side effect associated with its COVID-19 vaccine, known as Covishield in India, the UK pharmaceutical giant extended sympathy to those impacted. Reaffirming its dedication to patient safety amidst concerns about potential rare side effects, AstraZeneca emphasised the vaccine's overall safety profile. The company underscored the stringent standards of regulatory authorities to ensure the safe use of medicines, including vaccines. AstraZeneca highlighted the extensive clinical trial data and real-world evidence consistently supporting the safety and efficacy of the vaccine. (S...
Source: The Economic Times Healthcare and Biotech News - May 1, 2024 Category: Pharmaceuticals Source Type: news

Covishield Vaccine: Bereaved parents to take Serum Institute of India to Court following AstraZeneca's rare side effect admission
Covishield Vaccine Case: The parents of a woman allegedly deceased after receiving the Covishield vaccine plan to file a case against the Serum Institute of India (SII). This decision follows AstraZeneca's acknowledgment in court that their Covid shot can cause a rare side effect, providing hope for the parents in seeking justice. AstraZeneca faces a class-action lawsuit over allegations that its vaccine, developed with the University of Oxford, led to deaths and serious injuries, including thrombosis with thrombocytopenia syndrome (TTS), characterized by blood clots and low platelet count. (Source: The Economic Times Heal...
Source: The Economic Times Healthcare and Biotech News - April 30, 2024 Category: Pharmaceuticals Source Type: news

Covishield Case: Bereaved parents to take Serum Institute of India to Court following AstraZeneca's rare side effect admission
The parents of a woman allegedly deceased after receiving the Covishield vaccine plan to file a case against the Serum Institute of India (SII). This decision follows AstraZeneca's acknowledgment in court that their Covid shot can cause a rare side effect, providing hope for the parents in seeking justice. AstraZeneca faces a class-action lawsuit over allegations that its vaccine, developed with the University of Oxford, led to deaths and serious injuries, including thrombosis with thrombocytopenia syndrome (TTS), characterized by blood clots and low platelet count. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - April 30, 2024 Category: Pharmaceuticals Source Type: news

Sanofi introduces diabetes drug Soliqua in India
Sanofi India has launched its diabetes drug Soliqua in India, a once-daily injectable combination drug containing insulin and GLP-1 receptor agonist lixisenatide. The medication is available at a therapy cost of Rs 1,850 per pen and is indicated for adults with obesity and type 2 diabetes to improve glycemic control. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - April 30, 2024 Category: Pharmaceuticals Source Type: news

States seek more time for standard rates at hospitals
States, UTs, private hospitals seek more time for consultations on standard rates post Supreme Court directive. Court to hear plea by doctors, hospitals on government's rate prescription. Concerns raised on revenue impact. The order has led to widespread panic among private hospitals and investors, since standardisation of rates could substantially affect the revenue and commercial viability of hospital operations. Subsequently, healthcare providers wrote to the health ministry and the court, raising their concerns. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - April 29, 2024 Category: Pharmaceuticals Source Type: news